ALLEVIATE

Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis. What Happened Aldeyra said a Phase 3 trial, dubbed ALLEVIATE, that evaluated 0.25 percent and 0.5...